Oral Session 3-7A Multiple Myeloma: Daratumumab

[OS3-7A-4] Daratumumab, lenalidomide, and dexamethasone (D-Rd) in RRMM: cytogenetic risk analysis of POLLUX

Shinsuke Iida¹, Jonathan L. Kaufman², Meletios A. Dimopoulos³, Merav Leiba⁴, P Joy Ho⁵, Kihyun Kim⁶, Philippe Moreau⁷, Heather J Sutherland⁸, Jin Seok Kim⁹, H Miles Prince¹⁰, Albert Oriol¹¹, Nizar J. Bahlis¹², Ajai Chari¹³, Christopher Chiu¹⁴, David Soong¹⁴, Jon Ukropec¹⁵, Ming Qi¹⁴, Jesus San-Miguel¹⁶ (1.Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan, 2.Winship Cancer Institute, Emory University, Atlanta, GA, United States of America, 3.The National and Kapodistrian University of Athens, Athens, Hellenic Republic, 4.Sheba Medical Center, Tel Hashomer, Ramat Gan, State of Israel, 5.Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia, 6.Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, 7.Hematology, University Hospital Hôtel-Dieu, Nantes, France Metropolitan, 8.Leukemia/Bone Marrow Transplant Program, University of British Columbia, Vancouver, British Columbia, Canada, 9.Yonsei University College of Medicine, Severance Hospital, Seoul, Republic of Korea, 10.Cabrini Hospital, Epworth HealthCare and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia, 11.Institut Català d’Oncologia i Institut Josep Carreras, Hospital Germans Trias I Pujol, Barcelona, Spain, 12.University of Calgary, Arnie Charbonneau Cancer Institute, Calgary, Calgary, AB, Canada, 13.Icahn School of Medicine at Mount Sinai, New York, NY, United States of America, 14.Janssen Research & Development, LLC, Spring House, PA, United States of America, 15.Janssen Global Medical Affairs, Horsham, PA, United States of America, 16.Clínica Universidad de Navarra-CIMA, IDISNA, CIBERONC, Pamplona, Spain)